Atance Mireia, Serrano Cristina, Soto Carlos, Alonso-Domínguez Juan Manuel, Blas Carlos, Mata Raquel, Castaño Tamara, Perlado Sara, Arquero Teresa, López-Lorenzo Jose Luis, Pérez M Ángeles, Rosado Belen, Martos Rafael, Rio-Machin Ana, Llamas-Sillero Pilar, Salgado Rocio N, Serrano-López Juana
Hematology Department Hospital Universitario Fundación Jiménez Díaz UAM Madrid Spain.
Experimental Hematology Lab IIS-Fundación Jiménez Díaz UAM Madrid Spain.
EJHaem. 2025 May 28;6(3):e70059. doi: 10.1002/jha2.70059. eCollection 2025 Jun.
This study evaluates the prognostic value of bone marrow-derived mesenchymal stem cells (MSCs) in predicting the progression of Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML).
MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups.
A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation.
MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed.
The authors have confirmed clinical trial registration is not needed for this submission.
本研究评估骨髓间充质干细胞（MSC）在预测骨髓增生异常综合征（MDS）进展为急性髓系白血病（AML）中的预后价值。
在49例MDS患者队列中，包括转化组和未转化组，使用流式细胞术分析类MSC细胞。
在80%的诊断患者中鉴定出一个非造血性CD13明亮细胞群，富含MSC标志物CD105和CD90。这些类MSC细胞的升高与白血病早期进展和总生存期缩短显著相关。多变量分析证实MSC含量是白血病转化的独立预测因子。
MDS诊断时的类MSC细胞含量可能作为预测向AML恶性转化的一种新型生物标志物。需要在更大队列中进一步验证，并对该细胞群进行更好的表型特征描述。
作者已确认本提交内容无需临床试验注册。
